These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6783143)

  • 1. Survival analysis of drug combinations using a hazards model with time-dependent covariates.
    Stablein DM; Carter WH; Wampler GL
    Biometrics; 1980 Sep; 36(3):537-46. PubMed ID: 6783143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On determining the levels of treatment to optimize the probability of a favorable response.
    Carter WH; Wampler GL; Crews SL; Howells R
    Cancer Treat Rep; 1977 Aug; 61(5):849-53. PubMed ID: 408002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved method for analyzing survival data from combination chemotherapy experiments.
    Carter WH; Stablein DM; Wampler GL
    Cancer Res; 1979 Sep; 39(9):3446-53. PubMed ID: 476674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
    Wampler GL; Carter WH; Campbell ED; Goldman ID
    Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confidence interval about the response at the stationary point of a response surface, with an application to preclinical cancer therapy.
    Carter WH; Chinchilli VM; Campbell ED; Wampler GL
    Biometrics; 1984 Dec; 40(4):1125-30. PubMed ID: 6534413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single versus combination chemotherapy of L1210 leukemia.
    Koza I; Balázová E; Ujházy V
    Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P; Huong TH; Lhéritier J
    Bull Cancer; 1974; 61(4):509-26. PubMed ID: 4458834
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of tests of chemotherapeutic agents involving repeated drug treatment.
    Ullman NS; Jacquez JA
    Biometrics; 1973 Dec; 29(4):677-93. PubMed ID: 4785233
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of mathematical models for the evaluation of two- and three-drug combination chemotherapy in murine tumor models.
    Fichtner I; Steinhoff G
    Cancer Treat Rep; 1983; 67(7-8):621-9. PubMed ID: 6871880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models and their clinical correlations.
    Carter SK; Goldin A
    Natl Cancer Inst Monogr; 1977 Mar; (45):63-74. PubMed ID: 927496
    [No Abstract]   [Full Text] [Related]  

  • 11. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental basis of combination chemotherapy in the treatment of acute leukemia (author's transl)].
    Hoshino A
    Nihon Ketsueki Gakkai Zasshi; 1974 Oct; 37(5):731-9. PubMed ID: 4480565
    [No Abstract]   [Full Text] [Related]  

  • 13. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 14. [Carminomycin in combination with some cytostatics. 1. Efficacy in leukemia L1210].
    Nowak C; Arnold W; Henneberger G; Tanneberger S
    Arch Geschwulstforsch; 1983; 53(1):45-52. PubMed ID: 6860085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.
    Royston P; Parmar MK
    Stat Med; 2002 Aug; 21(15):2175-97. PubMed ID: 12210632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental approach for the search of effective drug combination in cancer chemotherapy.
    Bello JL; Kariev NI; Mainardi JV; Betancourt M; Lage A; Barroso MC; Alfonso L
    Neoplasma; 1982; 29(1):65-71. PubMed ID: 7070556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical designs for experiments in combination therapy.
    Miller I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):151-6. PubMed ID: 4826494
    [No Abstract]   [Full Text] [Related]  

  • 18. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
    Robak T; Szmigielska A
    Neoplasma; 2000; 47(3):168-71. PubMed ID: 11043840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical rationales for the selection of combinations of chemotherapeutic agents.
    Bono VH
    Cancer Chemother Rep 2; 1974 Mar; 4(1):131-6. PubMed ID: 4826492
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice.
    Valeriote F; Vietti T; Coulter D
    J Natl Cancer Inst; 1980 Apr; 64(4):801-5. PubMed ID: 6928994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.